Aclaris Therapeutics Inc (ACRS)

Apr 20, 2026

Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 - MSN

Apr 20, 2026

Apr 17, 2026

Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10 - Moomoo

Apr 17, 2026

Apr 17, 2026

Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Apr 17, 2026

Apr 17, 2026

Oppenheimer initiates coverage of Aclaris Therapeutics (ACRS) with outperform recommendation - MSN

Apr 17, 2026

Apr 16, 2026

ACRS Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus

Apr 16, 2026

Apr 16, 2026

Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target - Moomoo

Apr 16, 2026

Apr 16, 2026

Oppenheimer initiates Aclaris stock with Outperform rating By Investing.com - Investing.com Australia

Apr 16, 2026

Apr 16, 2026

Oppenheimer initiates Aclaris stock with Outperform rating - Investing.com

Apr 16, 2026

Apr 15, 2026

H.C. Wainwright reiterates Aclaris stock rating on drug trial data By Investing.com - Investing.com Canada

Apr 15, 2026

Apr 14, 2026

Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming - Yahoo Finance

Apr 14, 2026

Apr 14, 2026

Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4% - MarketBeat

Apr 14, 2026

Apr 13, 2026

Market Overview: What is the implied volatility of Aclaris Therapeutics Inc2026 Technical Patterns & Daily Growth Stock Tips - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Pullback Watch: Will Aclaris Therapeutics Inc benefit from AI trends2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn

Apr 11, 2026

Apr 09, 2026

ACRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 09, 2026

Apr 09, 2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Sahm

Apr 09, 2026

Apr 08, 2026

Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance UK

Apr 08, 2026

Apr 08, 2026

Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts - National Today

Apr 08, 2026

Apr 07, 2026

RA Capital Group reports 7.63M Aclaris shares (NASDAQ: ACRS) - Stock Titan

Apr 07, 2026

Apr 06, 2026

Forecast Cut: Why is Aclaris Therapeutics Inc stock going upMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn

Apr 06, 2026

Apr 04, 2026

ACRS PE Ratio & Valuation, Is ACRS Overvalued - Intellectia AI

Apr 04, 2026

Apr 04, 2026

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen - MarketBeat

Apr 04, 2026

Apr 02, 2026

Aug Macro: Is Bit Digital Inc a top pick in the sector2026 Reactions & Consistent Growth Equity Picks - baoquankhu1.vn

Apr 02, 2026

Apr 02, 2026

ACRS SEC FilingsAclaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 02, 2026

Apr 01, 2026

Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2%What's Next? - MarketBeat

Apr 01, 2026

Mar 31, 2026

Aclaris to present phase 2a ATI-2138 data at dermatology meeting - MSN

Mar 31, 2026

Mar 31, 2026

Aclaris completes enrollment in phase 2 trial of Bosakitug for atopic dermatitis - MSN

Mar 31, 2026

Mar 31, 2026

Aclaris Therapeutics' (ACRS) Outperform Rating Reaffirmed at Wedbush - MarketBeat

Mar 31, 2026

Mar 31, 2026

Aclaris Therapeutics (NASDAQ:ACRS) Shares Pass Below 50 Day Moving AverageShould You Sell? - MarketBeat

Mar 31, 2026

Mar 30, 2026

ACRS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 30, 2026

Mar 28, 2026

Analyst Upgrade: Why is Aclaris Therapeutics Inc stock going upMarket Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

Market Wrap: Why is Aclaris Therapeutics Inc stock going up2026 Retail & Weekly Top Gainers Alerts - baoquankhu1.vn

Mar 27, 2026

Mar 27, 2026

Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - Barchart

Mar 27, 2026

Mar 27, 2026

Aclaris Therapeutics Reports Positive Phase 2a Trial Results for ATI-2138 in Atopic Dermatitis, Showing Significant Improvements in Disease Severity and Quality of Life - Quiver Quantitative

Mar 27, 2026

Mar 27, 2026

Experimental eczema pill cut disease severity 77% in 12-week trial - Stock Titan

Mar 27, 2026

Mar 26, 2026

Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting - MyChesCo

Mar 26, 2026

Mar 26, 2026

Vanguard (ACRS) Amends Schedule 13G; Reports 0 Shares After Realignment - Stock Titan

Mar 26, 2026

Mar 26, 2026

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore

Mar 26, 2026

Mar 26, 2026

Published on: 2026-03-26 16:32:45 - baoquankhu1.vn

Mar 26, 2026

Mar 25, 2026

Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis - MyChesCo

Mar 25, 2026

Mar 23, 2026

Q1 EPS Estimate for Aclaris Therapeutics Raised by Analyst - MarketBeat

Mar 23, 2026